PMID- 35624416
OWN - NLM
STAT- MEDLINE
DCOM- 20220531
LR  - 20220716
IS  - 2731-4553 (Electronic)
IS  - 2731-4553 (Linking)
VI  - 23
IP  - 1
DP  - 2022 May 27
TI  - Predictors for successful weight reduction during treatment with Dapagliflozin 
      among patients with type 2 diabetes mellitus in primary care.
PG  - 134
LID - 10.1186/s12875-022-01748-1 [doi]
LID - 134
AB  - AIMS: Studies on factors affecting weight loss effect after start of 
      dapagliflozin in type 2 diabetes mellitus (T2DM) patients are few. The aim of 
      this study was to identify if there were any patient characteristics that could 
      predict weight loss after starting treatment with dapagliflozin. METHODS: The 
      study included 200 Korean patients with T2DM who were prescribed dapagliflozin in 
      a family medicine clinic during 2014-2019. We studied patients for 1 year after 
      starting dapagliflozin treatment. Data were collected from medical records. 
      Clinically meaningful weight reduction was defined as >/=3% decrease in body weight 
      and odds ratios (ORs) and 95% confidence intervals (CIs) for succeeding this 
      weight reduction was calculated for different baseline characteristics. RESULTS: 
      In total, 113 (56.5%) patients were male. Weight loss of >/=3% in 1 year treatment 
      with dapagliflozin was achieved in 122 (61%) patients. The likelihood of this 
      level of weight loss was significantly increased with regular exercise (OR 2.13, 
      95% CI 1.07-4.25), with concomitant metformin treatment (OR 2.90, 95% CI 
      1.23-6.80), and in patients with normal renal function (OR 13.84, 95% CI 
      1.33-144.26). Patients receiving sulfonylurea treatment were less likely to 
      achieve >/=3% weight reduction (OR 0.39, 95 CI 0.19-0.79). CONCLUSIONS: T2DM 
      patients that performed regular exercise, had normal renal function and were 
      receiving metformin were more likely to have clinically meaningful body weight 
      reduction after one year treatment with dapagliflozin.
CI  - (c) 2022. The Author(s).
FAU - Huh, Youn
AU  - Huh Y
AD  - Department of Family Medicine, Uijeongbu Eulji Medical Center, Eulji Unversity, 
      Gyeonggi-do, Republic of Korea.
FAU - Kim, Young Sik
AU  - Kim YS
AD  - Department of Family Medicine, Asan Medical Center, University of Ulsan College 
      of Medicine, 88 Olymphic-Ro 43-Gil, Songpa-gu, Seoul, 05505, Republic of Korea. 
      youngkim@amc.seoul.kr.
LA  - eng
PT  - Journal Article
DEP - 20220527
PL  - England
TA  - BMC Prim Care
JT  - BMC primary care
JID - 9918300889006676
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Benzhydryl Compounds
MH  - Body Weight
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Female
MH  - Glucosides
MH  - Humans
MH  - Male
MH  - *Metformin/therapeutic use
MH  - Primary Health Care
MH  - Weight Loss
PMC - PMC9137162
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - Primary health care
OT  - Sodium-glucose transporter 2 inhibitor
OT  - Weight loss
COIS- The authors declare that they have no competing interests.
EDAT- 2022/05/28 06:00
MHDA- 2022/06/01 06:00
PMCR- 2022/05/27
CRDT- 2022/05/27 23:29
PHST- 2021/08/28 00:00 [received]
PHST- 2022/05/04 00:00 [accepted]
PHST- 2022/05/27 23:29 [entrez]
PHST- 2022/05/28 06:00 [pubmed]
PHST- 2022/06/01 06:00 [medline]
PHST- 2022/05/27 00:00 [pmc-release]
AID - 10.1186/s12875-022-01748-1 [pii]
AID - 1748 [pii]
AID - 10.1186/s12875-022-01748-1 [doi]
PST - epublish
SO  - BMC Prim Care. 2022 May 27;23(1):134. doi: 10.1186/s12875-022-01748-1.